Annually, out-of-pocket costs paid by 86.5 to 95.2 percent of patients for evaluation/management visits
WEDNESDAY, Dec. 23 2020 (HealthDay News) — From 2001 to 2016, out-of-pocket costs of evaluation and management (E/M) services and common diagnostic tests increased for neurology patients, according to a study published online Dec. 23 in Neurology.
Chloe E. Hill, M.D., from the University of Michigan in Ann Arbor, and colleagues used a large, privately insured health care claims database to measure out-of-pocket costs for E/M services and common diagnostic testing for neurology patients from 2001 to 2016. Data were included for 3,724,342 patients.
The researchers found that E/M visits, electromyogram/nerve conduction studies , magnetic resonance imaging (MRI), and electroencephalograms (EEGs) were the most frequent neurologic services (78.5, 7.7, 5.3, and 4.5 percent, respectively). Annually, out-of-pocket costs were paid by 86.5 to 95.2 percent of patients for E/M visits and by 23.1 to 69.5 percent of patients for diagnostic tests. The mean out-of-pocket cost increased over time, with the most substantial increases seen for EEG, MRI, and E/M visits. There was considerable variation noted in out-of-pocket costs; the 50th and 95th percentile paid $103.1 and $875.4, respectively, for an MRI in 2016. The investigators also observed an increase in the proportion of total service cost paid out of pocket.
“This trend of increased out-of-pocket costs could be harmful, as people may forgo diagnostic evaluation due to costs, or those who complete diagnostic testing may be put in a position of financial hardship before they can even start to treat their condition,” Hill said in a statement.
Several authors disclosed financial ties to the medical device and medical-legal industries.
Abstract/Full Text (subscription or payment may be required)
Maternal Night-Shift Work Tied to Later Neurodevelopmental Issues in Offspring
More Extensive Deposits of Tau Seen in Early-Onset Alzheimer Disease
Low Levels of Placental Growth Factor in Pregnancy Linked to Subsequent ADHD in Offspring
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer
Pre-Prostate Biopsy MRI Use Increased From 2017 to 2026
ASTRO Issues Guidance for Use of Radiation Therapy in Bladder Cancer
Higher Intake of Saturated, Animal Fats May Increase Mortality in Prostate Cancer
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer